The localization of the two major placental glucose transporter isoforms, GLUTi and GLUT3 was studied in 20-d pregnant rats. Immunocytochemical studies revealed that GLUTi protein is expressed ubiquitously in the junctional zone (maternal side) and the labyrinthine zone (fetal side) of the placenta. In contrast, expression of GLUT3 protein is restricted to the labyrinthine zone, specialized in nutrient transfer. After 19-d maternal insulinopenic diabetes (streptozotocin), placental GLUT3 mRNA and protein levels were increased four-to-fivefold compared to nondiabetic rats, whereas GLUTi mRNA and protein levels remained unmodified. Placental 2-deoxyglucose uptake and glycogen concentration were also increased fivefold in diabetic rats. These data suggest that GLUT3 plays a major role in placental glucose uptake and metabolism.
Introduction
Glucose is the major fuel for growth and energy metabolism of feto-placental tissues (reviewed in reference 1, 2). One of the major functions of the placenta is to ensure adequate transfer of glucose from maternal to fetal circulation. Glucose transport across the cell membrane occurs through a stereospecific, saturable, and facilitative diffusion process dependent on glucose transporter proteins. At least five different facilitative glucose transporters encoded by separate genes (GLUTI -5) have been characterized in mammalian tissues (reviewed in reference 3, 4) . Among these transporters, GLUTI and GLUT3 proteins are predominantly expressed in human and rat placenta (5) (6) (7) (8) . The mRNAs of these two major placental glucose transporter isoforms have been recently localized in the rat by in situ hybridization. GLUTI mRNA has been found in regions of high glucose metabolism, whereas GLUT3 mRNA is expressed in regions devoted to nutrient transfer processes (9) . However, the localization and the regulation of placental GLUTI and GLUT3 proteins have not been determined.
In general, glucose transporter mRNA and protein expression are controlled in vivo by the metabolic and hormonal status. In the rat, long-term insulinopenic diabetes results in increased liver GLUT2 mRNA (10) and decreased GLUT4 mRNA levels in skeletal muscle (I 1) and adipose tissue (12) . In vitro, glucose deprivation increases GLUTI mRNA and protein levels in adipose and muscle cell lines (13, 14) . Thus, changes in glucose and insulin levels appear to be important modulators of the expression of several facilitative glucose transporters.
Although the placenta contains a large number of insulin receptors located on trophoblast cells (15) , placental glucose transport is not likely to be regulated by insulin (16) (17) (18) . This is strengthened by the observation that the insulin-responsive glucose transporter isoform, GLUT4 is expressed at very low levels in the placenta (6, 9) . By contrast, placental glucose transport is closely related to maternal plasma glucose concentration (1, 19) , suggesting that placental glucose transporter(s) expression might be regulated by glucose. This is supported by the findings that glucose transport from the mother to the fetus is enhanced in diabetic rats (20) . Furthermore, diabetes in human pregnancy is associated with abnormalities in feto-placental growth, and it has been hypothesized that maternal hyperglycemia could lead to fetal growth alterations, i.e., feto-placental macrosomia and congenital malformations (21) (22) (23) . This also favors a major role for maternal glucose homeostasis in fetoplacental development.
The aims of the present study were: (a) to localize rat placental GLUTi and GLUT3 proteins and to assess their respective role in the transfer of glucose from maternal to fetal circulation; (b) to study the expression of GLUTI and GLUT3 transporter isoforms in placentas of insulinopenic diabetic rats; and (c) to determine the effect of hyperglycemia on the regulation of placental GLUT3 mRNA and protein expression. (24) . Euglycemic hyperinsulinemic clamps were performed as previously described (25 7 .4 then frozen at -80OC before use. Crude membranes from rat brain were prepared as previously described (26) .
Immunoblotting. Equal amounts of membrane proteins (100 pg)
were solubilized in Laemmli buffer without heating (27) and once for 30 min with 0.1 x SSC/0.1% SDS at 550C, then exposed for 6-24 h at -800C with intensifying screens. Quantification of the specific signals was performed by scanning densitometry. After stripping of the glucose transporter probes, the blots were rehybridized with an antisense synthetic oligonucleotide (24 mer) specific for the 18S ribosomal subunit to correct for the exact amount of RNA transferred to the filters (30) .
In vivo measurement of placental 2-deoxyglucose uptake. The method used for measuring placental glucose uptake has been described previously (17 compared GLUT3 mRNA levels in placenta, brain, and testis, three tissues reported to specifically express this glucose transporter isoform. The highest levels of GLUT3 mRNA were observed in testis and placenta whereas lower levels were found in brain. This might be due to the fact that neuronal cells only are a major site for GLUT3 expression (32) . GLUTI mRNA levels were determined in the same tissues. Highest expression was observed in placenta ( Fig. 1) .
Localization ofplacental GLUT] and GLUT3 glucose transporters by imrnmunofluorescent staining. The localization of GLUTi and GLUT3 proteins was studied on parasagittal sections of placentas obtained from three pregnant rats (day 20 of gestation). The junctional and labyrinthine zones of the rat placenta were identified by the size of their nuclei. The cytotrophoblast cells of the junctional zone have larger nuclei than those of the labyrinthine cells (14-18 jm and 4-6 pm, respectively). The size of the nuclei was determined on tissue sections stained with Hoescht dye (Fig. 2 C, and Fig. 3, B and D) . After incubation of serial semithin placental sections with anti-GLUTI and anti-GLUT3 antibodies, a unipolar distribution of GLUT3 protein (Fig. 2 B) was first detected at a low magnification (X 100); it was distinct from the homogeneous distribution of GLUTi protein (Fig. 2 A) . At a higher magnification (x400) GLUTi protein was found in both the junctional zone which corresponds to the interface between maternal and fetal tissues and the labyrinthine zone (Fig. 3 A) specialized for maternofetal exchanges. GLUT3 protein was found exclusively in the labyrinthine zone (Fig. 3 C) . However it was impossible to determine the precise location of GLUT3 and GLUTi proteins within a specific layer of the placental barrier by light microscopy.
Characterization of placental GLUT3 glucose transporter. GLUT3 glucose transporter was detected in postnuclear placental and brain membranes prepared from 19-d pregnant rats. Specificity of the detection was determined by competition with an homologous mouse GLUT3 peptide. In the absence of GLUT3 peptide, a broad diffuse signal composed of several bands migrating between 46 and 90 kD was detected in the placenta, whereas in the brain, a major band was observed at 45-55 kD (Fig. 4 A) Table I . Diabetic pregnant rats were hyperglycemic (449±11 mg/dl vs 91±2 mg/dl, P < 0.001) and hypoinsulinemic (4±1 1U/ml vs 37±3. /sU/ml, P < 0.001). Placental weights were higher in diabetic than in control rats (P < 0.01). By contrast, fetal weights were lower in diabetic rats (P < 0.001). The placental levels of GLUTI and GLUT3 mRNAs were assessed by Northern blot analysis. Three Northern blots were performed independently using total RNA extracted from placentas of 9 STZ and 11 control rats. Quantification of the autoradiographic signals showed that GLUTir mRNA levels were similar in placentas of diabetic and control rats whereas GLUT3 mRNA levels were increased fivefold (P < 0.001) in placentas of diabetic compared to those of control rats (Fig. 5) .
Effect of diabetes on placental GLUT] and GLUT3 protein (Fig. 6,  top) . The broadness of the bands is characteristic of heavily glycosylated proteins as has been previously shown in the human placenta (33) . By contrast, the brain GLUT1 and GLUT3 isoforms were detected as narrow 45-50 kD bands (Fig. 6 , bottom). GLUT1 protein level was similar in placentas of diabetic and control rats, whereas GLUT3 protein levels were increased threefold in placenta from diabetic rats. When quantitated by densitometry and expressed in arbitrary units, the mean values were 30±1.9 in placentas from diabetic rats compared to 7.6±0.8 in placentas from control rats (P < 0.002) (Fig. 6 ).
Since diabetes did not induce any modifications in the amount of brain glucose transporters, these data clearly show that diabetes specifically induced an overexpression of GLUT3 in the placenta at both the mRNA and protein levels. Regulation of GLUT3 expression in diabetic rats. To evaluate the role of hyperglycemia in the regulation of GLUT3 expression, six STZ-diabetic rats were treated with phlorizin from day 15 to 20 of gestation. Phlorizin infusion resulted in a significant decrease in maternal plasma glucose levels from 440±11 to 248±23 mg/dl, with no change in plasma insulin levels (Table II) . Quantitation of specific signals by scanning densitometry showed that under these conditions, GLUT3 mRNA and protein levels were decreased 2. 4.5±0.5 arbitrary units) and 3-fold (30±1.9 vs 9.7±2.4 arbitrary units), respectively, compared to diabetic rats (Fig. 7) . Placental 2-deoxyglucose uptake and glycogen concentration in control and diabetic rats. Placental 2-deoxyglucose uptake and glycogen concentration were determined in 19-d control and diabetic pregnant rats. Both parameters were fivefold higher in placentas from diabetic compared to control rats (Table III). Since protein concentrations were unmodified in diabetic and control placentas, the results were similar when expressed per milligram tissue wet weight or milligram protein. This indicates an increase in the overall placental glucose utilization and storage ability in placentas of diabetic animals. Effects ofmaternal hyperglycemia and hyperinsulinemia on placental GLUT] and GLUT3 mRNA levels. Hyperglycemic clamps were performed for 6 or 12 h in awake, unrestrained 20-d pregnant rats to determine the short-term effect of hyperglycemia on GLUTI and GLUT3 mRNAs. Maternal glucose concentrations were raised and clamped at 655+12 mg/dl and 613±45 mg/dl, respectively, resulting in a maternal insulinemia of 130±12 ,iU/mI after 6 h and 450+30 ,U/ml after 12 h (Table   II) . Placental GLUTI and GLUT3 mRNA levels were not altered after 6 h whereas GLUT3 mRNA concentration was increased three-to fourfold after the 12 h hyperglycemia (Fig.  8) . Euglycemic-hyperinsulinemic clamps were also performed to evaluate a possible effect of changes in maternal insulinemia. Maternal plasma glucose concentration was thus clamped at 96+4 mg/dl whereas plasma insulin was raised to 4,820+205 ,U/mi during 12 h (Table II) . Under these conditions, placental GLUTI and GLUT3 mRNA levels were not modified (Fig. 8 ).
Discussion
The rat placenta is composed of two main regions, the junctional and the labyrinthine zones. The junctional zone (maternal side) $ --| (9) (5) _ _
At the end of the experiment, corresponds to the interface between the maternal and fetal tissues, and is the site of trophoblast proliferation. The labyrinthine syncytiotrophoblast layer (fetal side) is specialized in materno-fetal exchanges, and is also referred to as the placental barrier (34) . Using light microscopic immunohistochemistry, we found that GLUT3 protein was exclusively localized in the labyrinthine zone whereas GLUTI protein was detected both in the labyrinthine and junctional zones (Figs. 2 and 3 ). These observations are consistent with data obtained by in situ hybridization in the rat placenta showing an homogeneous distribution of GLUTI and GLUT3 mRNAs in the labyrinthine zone (9) , and by immunohistochemistry in the mouse placenta showing an homogeneous distribution of GLUTi and GLUT3 proteins in the same region (35) . Although the precise localization of GLUTI and GLUT3 proteins within the trilaminar placental barrier requires electron microscopic studies, the presence of GLUT3 protein in the region of materno-fetal exchanges suggests that this isoform could be specifically involved in the transfer of glucose from mother to the feto-placental unit. In the rat brain, GLUTI protein is detected in the microvessels of the blood-brain barrier (28, 36, 37) whereas GLUT3 is localized in neuronal cells (32, 37, 38) . The localization of GLUTI and GLUT3 proteins in specific brain areas have led to the hypothesis of a preferential transfer of glucose from blood to neuronal cells (28) . Based on the observation that the low Km GLUT3 transporter is expressed at highest levels in tissues with an hematotissular barrier, i.e. brain, testis, and placenta (28, 39, and Fig. 1) , it is tempting to speculate that this transporter isoform would serve preferentially to ensure a vectorial transport of glucose from the maternal to the fetal circulation, as proposed by Zhou and Bondy (9) . Thus, mechanisms similar to those described in the brain could also prevail in the placenta to deliver maternal glucose to meet specific metabolic adaptations within tissues of the feto-placental unit.
GLUTi and GLUT3 proteins were also readily detected in the placenta by immunoblotting. Both glucose transporter isoforms appear heavily glycosylated as shown by the broad range of migration on SDS-PAGE (Figs. 4 and 6 ). The major immunoreactive bands detected with the anti-GLUT3 antibody are effectively competed by an homologous GLUT3 peptide, indicating that this heavily glycosylated protein represents GLUT3 glucose transporter isoform (Fig. 4 A) . Glycosidase digestion before electrophoresis and immunoblotting confirms that placental GLUT3 protein contains N-linked oligosaccharides (Fig. 4 B) as previously reported for most glucose transporter isoforms, including GLUT3 (7, 26, 37) . A high level of glycosylation seems a characteristic of placental tissue since only lower molecular weight isoforms of GLUT3 are detected in brain and testis (26, 37, 39) , two other tissues expressing high levels of GLUT3. By contrast the heavy glycosylation pattern of placental GLUTI protein appears as a more constant feature of GLUTI isoform as observed in several tissues and cells including erythrocytes, liver, and adipocytes (26, 40) . The fivefold increase in placental glucose uptake and glycogen concentration found in diabetic rats (Table III) confirms previous reports showing an increase in placental glucose transfer and utilization in STZ-diabetic pregnant rats (20, 41) as well as in placental glycogen concentration in diabetic human (42) , mouse (35) , and rat (43).
Since GLUTi mRNA and protein levels remained unchanged in the placenta of diabetic rats (Figs. 5 and 6), this glucose transporter isoform cannot be implicated in the placental metabolic changes observed in diabetes. By contrast, the four-to fivefold increase in GLUT3 mRNA and protein expression in placentas of diabetic rats suggests that GLUT3 could be responsible for the enhanced glucose uptake and glycogen accumulation. An increase in placental GLUT3 mRNA levels has also been recently reported in diabetic pregnant mice (35) . The 30% increase in the placental weight of diabetic rats (20, 33, and Table I ) is unlikely to account for the fourfold increase in GLUT3 expression and the fivefold increase in glucose uptake and glycogen accumulation. These adaptations favor the idea that the placenta cannot be regarded as a simple filter between the mother and the fetus. Under certain pathological conditions, it could also function as a reservoir to prevent an accelerated flux of maternal glucose toward the fetal circulation.
The overexpression of placental GLUT3 could also contribute to maintain a positive materno-fetal glucose gradient to supply an adequate flux of glucose to the fetus. This would in turn limit fetal growth retardation since the diabetic fetus is clearly not capable of using glucose at a normal rate.
The potential role of maternal hyperglycemia in the stimulation of GLUT3 expression was evaluated by lowering maternal glycemia. Infusing phlorizin to the diabetic pregnant rats induced a two-to threefold decrease in maternal plasma glucose levels maintained for 5 d (without any concomitant change in insulin levels). This resulted in a twofold decrease in GLUT3 mRNA and protein levels (Fig. 7) and suggests that maternal hyperglycemia plays a major role in the increase in GLUT3 mRNA and protein levels observed in diabetes. A different type of regulation is more likely to prevail in the brain since GLUT3 protein expression was neither increased by insulinopenic diabetes in adult rats (Fig. 6 ) and mice (44) nor in rat fetuses (45, 46) . To establish the respective role of glycemia and insulinemia in the modifications of GLUT3 gene expression, we performed euglycemic hyperinsulinemic, and hyperglycemic clamps in 20-d pregnant rats. Supraphysiologic plasma insulin levels maintained during 12 h in pregnant rats (> 4,000 pU/ml) did not increase placental GLUT3 gene expression (Table II, Fig. 8 ), suggesting that maternal insulinemia is not involved in the regulation of GLUT3 mRNA levels. By contrast, placental GLUT3 mRNA levels were enhanced threefold after 12 h hyperglycemic clamps (Fig. 8) . The similar increase in GLUT3 mRNA levels observed under short-term hyperglycemia and long-term diabetes supports the idea that hyperglycemia per se could be responsible for the regulation of placental GLUT3 gene expression.
The mechanisms involved in the regulation of placental GLUT3 expression by glucose have not been defined in the present study. However, the expression of an increasing number of genes implicated in glucose metabolism have been shown to be regulated by one or several metabolites (glucose-6-phosphate or a metabolite of the hexosamine pathway) possibly via a glucose responsive sequence located in the 5' flanking region of these genes (47) (48) (49) (50) . Whether or not the regulation of placental GLUT3 expression involves similar mechanisms remains to be determined. In this respect, studies of transcriptional steps will contribute to further understand the modifications of placental GLUT3 gene expression induced by maternal hyperglycemia.
In summary, this study provides the first evidence that GLUT3 mRNA and protein expression can be stimulated in vivo under various hyperglycemic conditions. These findings might be of major importance to establish the specific contribution of GLUT3 glucose transporter to the overall regulation of placental glucose transport and utilization. Further characterization of placental GLUT3 gene expression will help to shed light on severe pregnancy-associated disorders such as those encountered in diabetes (macrosomia, malformations) and intrauterine growth retardation (hypoglycemia, low birth weight).
